A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This trial is a phase I clinical trial of a SARS‐CoV‐2 Bivalent mRNA Vaccine (LVRNA021). The trial used a randomized, blinded, placebo‐controlled design to evaluate the safety, tolerability, and preliminary immunogenicity of the trial vaccine in participants Aged 18 Years and Older who had received SARS‐CoV‐2 Vaccine.
Epistemonikos ID: f1025855a1ecf1c0c2db0f80db8c242b25141b58
First added on: Jul 13, 2023